Guggul

Guggul (Commiphora wightii): A Comprehensive Reference

1. Identity and Natural Source

Botanical and Chemical Names

Guggul (also spelled Guggulu or Guggal) is an oleo-gum resin which exudes from the bark of Commiphora wightii (Arnott) Bhandari [synonyms: Commiphora mukul (Hook. ex Stocks) Engl.; Balsamodendron mukul (Hook. ex Stocks); Family: Burseraceae]. The plant is known as Indian bdellium in English, as Mahisaksha, Guggulu, Amish, Pilanksha, and Pur in Sanskrit, and as Guggul in most Indian languages. It is in the same genus as Commiphora myrrha, the myrrh mentioned in the Bible.

Natural Habitat and Source

Commiphora wightii is a branched shrub or small tree (2–3 m high) found in some states of India and Pakistan. The wild occurrence of this species is restricted mainly to the dry regions of Rajasthan and Gujarat States of India, and the bordering regions of Pakistan. There has been a decline in its wild population over the last several decades, as a result of habitat loss and degradation coupled with unregulated harvesting and tapping of oleo-gum resin. This species is consequently assessed as Critically Endangered and enlisted in the IUCN Red List of threatened species.

The Resin: How It Is Obtained

The gum, called "guggul" or "gum guggulu," is tapped from the stem of the plant, and the fragrant yellow latex solidifies as it oozes out. Excessive production of the gum eventually kills the plant. Guggulu consists of oleo-gum resin obtained as an exudate from the tapping of stem and branches of Commiphora wightii.

Common Forms and Preparations

Guggul is available in various forms, including capsules and tablets, and is often used as a herbal supplement to support healthy cholesterol levels. In traditional Ayurvedic practice, raw resin undergoes a purification step called śodhana: Further boiling is continued until the guggulu solution forms a soft mass. It is then poured out over a smooth wooden board smeared with cow ghee or castor oil and dried in the sun. The dried mass is called purified guggulu (suddh guggulu). Modern commercial preparations are typically standardized extracts sold under trade names such as gugulipid or guggulipid, with standardization often expressed as a percentage of guggulsterone content (e.g., 2.5% guggulsterones in extracts used in clinical trials). Gum guggul is also used in incense, lacquers, varnishes, and ointments, as a fixative in perfumes, and in medicine.

---

2. Traditional and Historical Use

Ayurvedic Tradition (India)

Commiphora wightii is recognized for its oleo-gum-resin, which has been valued in Ayurveda for over 3,000 years. Historically, Guggulu has been mentioned as far back as 600 BCE in classical Ayurvedic texts like the Charaka Samhita and Sushruta Samhita. In Charaka, it is referred to as a kapha-vata pacifier, recommended in formulations such as Guggulu Ghruta. Dating as far back as 1700 BCE, Guggulu has been revered in ancient Ayurvedic texts, including the Sushruta Samhita, which describes its use in treating internal tumors, sores, obesity, liver dysfunction, intestinal worms, leukoderma, sinus, and edema when taken orally.

The Sushruta Samhita describes it as a potent anti-krimi (anti-parasitic) agent, while Vagbhata's Ashtanga Hridaya lists it under Prishta Rasayanas for rejuvenation. Ancient physicians prized guggulu for joint disorders (Sandhivata), obesity, and skin diseases. It has been used in Ayurveda since time immemorial for the treatment of a variety of disorders such as inflammation, gout, rheumatism, obesity, and disorders of lipid metabolism.

Unani Medicine

The extract of gum guggul, called gugulipid, guggulipid, or guglipid, has been used in Unani and Ayurvedic medicine for nearly 3,000 years in India. Its uses in Unani practice parallel Ayurvedic applications, particularly regarding inflammatory conditions and metabolic disorders.

Classical Compound Formulations

Guggulu's most important classical expressions are as compound preparations, not as a standalone supplement. Several of these formulas have been used in Ayurvedic clinical practice for centuries and are still produced by traditional Ayurvedic pharmacies today.

• Triphala Guggulu: Combines Guggulu with Triphala (the three-fruit compound) and long pepper. The Ashtanga Hridayam describes this formula as having particular relevance to conditions involving Kapha and Ama in the channels, and it is one of the most widely used classical Guggulu preparations in traditional practice.
• Yogaraj Guggulu: One of the most complex classical Guggulu formulas, containing Guggulu alongside twenty-eight supporting herbs. The Sahasrayogam and Bhaishajya Ratnavali describe it in the context of supporting joint mobility, the musculoskeletal system, and the clearance of Vata-related accumulations in the channels.
• Kanchanar Guggulu, Punarnavadi Guggulu, and others: The Ayurvedic Formulary of India devotes an entire section to guggulu-based medicines, reflecting the breadth of its classical use.

Traditional Therapeutic Scope

The plant has been used in the traditional Ayurvedic medical system for centuries in the treatment of a variety of disorders, most notably arthritis and as a weight-reducing agent in obesity. Other traditional uses have included liver dysfunction, tumors, ulcers and sores, urinary complaints, intestinal worms, edema, seizures, and as a cardiac tonic. Further therapeutic uses documented in traditional literature include treatment of nervous diseases, leprosy, muscle spasms, ophthalmia, skin disorders, ulcerative pharyngitis, hypertension, ischaemia, and urinary disorders.

Early Modern Research History

The first scientific study on guggul, published in 1966, focused on its influence on lipid metabolism, particularly the relationship between obesity and arteriosclerosis. In 1966, the first medical studies in animals were conducted, and in 1986 guggul gained wider research attention.

---

3. Key Constituents and Active Compounds

Overall Phytochemical Profile

Guggulu contains diterpenoids, triterpenoids, steroids, long-chain aliphatic tetrols, aliphatic esters, ferulates, lignans, carbohydrates, and a variety of inorganic ions, besides minor amounts of sesamin and other unidentified constituents. It is a mixture of phytoconstituents, including volatile oil containing terpenoidal constituents such as monoterpenoids, sesquiterpenoids, diterpenoids, and triterpenoids; steroids; flavonoids; guggultetrols; lignans; sugars; and amino acids. Guggul resin is a complex mixture of various classes of chemical compounds, such as lignans, lipids, diterpenoids, and steroids.

Primary Bioactive Compounds: Guggulsterones

The main active constituents of this oleo-gum resin are Z-guggulsterone, E-guggulsterone, Z-guggulsterol, and guggulsterol I–V. These are steroidal compounds (specifically, pregnanediones) classified as plant sterols. The E- and Z-isomers of guggulsterone are the most pharmacologically studied of all constituents. Guggulsterones have also been reported to regulate gene expression by exhibiting control over molecular targets including transcription factors such as nuclear factor (NF)-κB, signal transducer and activator of transcription (STAT), and steroid receptors.

Volatile Oil

The gum resin of C. wightii yields about 0.4% of essential oil by steam distillation, and its chief components are myrcene, dimyrcene, and polymyrcene. Other components of the oil are eugenol, d-limonene, α-pinene, (±) linalool, cineole, α-terpineol, d-α-phellandrene, methylheptanone, bornyl acetate, (±) geraniol, and some other unidentified compounds.

Other Notable Compounds

Bioactivity-directed fractionation studies have identified additional active components: Z- and E-guggulsterones were the most potent inhibitors of nitric oxide production (IC₅₀ values of 1.1 and 3.3 μM, respectively, compared to curcumin at IC₅₀ 12.3 μM), followed by myrrhanol A and myrrhanone A (IC₅₀ values of 21.1 and 42.3 μM, respectively). Over a hundred metabolites of various chemical compositions have been reported from the leaves, stem, latex, root, and fruit samples.

---

4. Mechanisms of Action

Farnesoid X Receptor (FXR) Antagonism

The most extensively studied molecular mechanism involves guggulsterone's interaction with nuclear receptors governing bile acid and cholesterol metabolism. Bile acids activate a nuclear receptor, farnesoid X receptor (FXR), that induces bile salt export pump (BSEP) but inhibits cholesterol 7α-hydroxylase (CYP7A1) gene transcription in the liver. Guggulsterone, a plant sterol that lowers serum cholesterol, has been shown to antagonize FXR-activated genes.

Conversion of cholesterol to bile acids in the liver is initiated by the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1), and excretion of bile acids from the liver is mediated by the bile salt export pump (BSEP). The expression of CYP7A1 and BSEP is coordinately regulated by a negative feedback and positive feed-forward mechanism, respectively, through bile acid-mediated activation of FXR. Guggulsterone synergistically induces the expression of BSEP in cells treated with FXR agonist bile acids. As an FXR antagonist, guggulsterone presumably decreases SHP (small heterodimer partner) and consequently increases CYP7A1 expression, also favoring cholesterol metabolism.

Guggulsterone, the active principle of guggulipid, has been used in ethnic medicine for thousands of years for its anti-inflammatory and antilipidemic activities. The activities appear to be mediated by its interaction with an array of nuclear receptors, including endocrine steroid receptors and metabolic lipid receptors. Although relatively weak, the activity at the metabolic farnesoid X receptor (FXR) is particularly intriguing, as guggulsterone is, so far, the only known antagonist for this receptor, with a peculiar ability of gene-selective modulation.

It should be noted that the exact role of FXR antagonism in the clinical cholesterol-lowering effect of guggul remains under debate, and the relationship between this mechanism and observed human outcomes has not been fully resolved.

NF-κB Pathway Inhibition (Anti-Inflammatory Mechanism)

Treatment with guggulsterone downregulated RANKL-induced osteoclastogenesis and blocked IL-1β-mediated production of chemokines and epithelial neutrophil activating peptide-78 (ENA-78), MMP-1, and MMP-3, via suppression of NF-κB, nuclear p50, and p65 subunit, and IκBα degradation in rheumatoid arthritis models. A study on IBD showed that guggulsterone inhibited IL-1β- or lipopolysaccharide (LPS)-induced ICAM-1 expression, NF-κB transcription activity, and IκB phosphorylation/degradation in human Caco-2 cells and rat non-transformed IEC-18 cells.

COX-2 and Additional Inflammatory Targets

Various molecular pathways, such as cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), PI3-kinase/AKT, JAK/STAT, nitric oxide synthase (iNOS), and NF-κB signaling pathways, have been targeted to assess the anti-arthritic and anti-inflammatory effects of guggulipid. Research findings reveal that guggulipid demonstrates notable anti-arthritic and anti-inflammatory effects by targeting these key molecular pathways involved in inflammatory responses.

Thyroid Stimulation

Animal studies have reported that Z-guggulsterone can stimulate thyroid hormone production, specifically triiodothyronine (T3), which could partly explain proposed metabolic and lipid-lowering effects via an indirect route. However, this evidence comes from animal models, and no large human trials have confirmed the same thyroid-boosting effect.

---

5. Scientific Evidence by Area of Use

5.1 Lipid Metabolism and Hypercholesterolaemia

This has been the most researched area in human trials, with results that are decidedly mixed.

Earlier Indian trials (pre-2003): Before 2003, most scientific evidence suggested that guggulipid elicits significant reductions in serum total cholesterol, low-density lipoprotein (LDL), and triglycerides, as well as elevations in high-density lipoprotein (HDL). However, most published studies were small and methodologically flawed.

The landmark 2003 JAMA trial (Szapary et al.): Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents. Guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of 2 nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects of these extracts. Despite this mechanistic rationale, in August 2003, this well-designed trial reported small but significant increases in serum LDL levels associated with the use of guggul compared to placebo. No significant changes in total cholesterol, high-density lipoprotein (HDL), or triglycerides were measured.

A 2020 European RCT (Guggulu and Triphala): This was a parallel, randomized, double-blind controlled trial that included 90 individuals at low-to-moderate cardiovascular risk. At intention-to-treat analysis, from baseline to 3 months, total serum cholesterol decreased by 1.9% in the placebo group and 3.3% in the intervention group (p = 0.01). Serum LDL-C decreased by 4.9% and 4.8% in the placebo and intervention groups, respectively, without significant differences between them. Three months of treatment with Guggulu and Triphala did not show better effects than placebo on serum levels of total and LDL cholesterol, BMI, or waist circumference.

Systematic review and meta-analysis (PMC8229657): A systematic review and meta-analysis encompassing 1,386 participants across 32 studies, focused on the effects of guggul on hypercholesterolaemia. The key findings indicated that guggul reduced total cholesterol by 16.78 mg/dL and LDL cholesterol by 18.78 mg/dL, although the study noted variability in quality and dosing regimens across the included studies.

Overall assessment: The effects of guggulipid in patients with high cholesterol are not clear, with some studies finding cholesterol-lowering effects, and other research suggesting no benefits. At this time, there is not enough scientific evidence to support the use of guggul for any medical condition. Its primary therapeutic use is for managing high cholesterol levels, although scientific evidence on its effectiveness remains mixed, with some studies indicating potential benefits while others do not support this claim.

5.2 Inflammation and Arthritis

Apart from its lipid effects, the effect of guggul has been demonstrated against different inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD), and various other conditions.

Osteoarthritis (human study): As guggul has been reported to exhibit high activity against arthritis pre-clinically, its effect was evaluated in the clinical setting. In one study, 30 patients with arthritis were treated with gum guggul for 1 month, which resulted in remarkable improvement in the total scores of the Western Ontario and MacMaster Osteoarthritis Index (WOMAC) and overall condition of the patients. A clinical study evaluating a traditional guggul-based preparation in patients with knee osteoarthritis found significant pain reduction over 84 days of treatment. Pain scores on a standard 10-point scale dropped from an average of 6.71 at baseline to 3.91 at end of treatment. A more detailed pain assessment showed scores cut roughly in half, from 10.31 to 5.09.

Rheumatoid arthritis (preclinical and in vitro): Various molecular pathways, including COX-2, VEGF, PI3-kinase/AKT, JAK/STAT, iNOS, and NF-κB signaling pathways, have been targeted to assess the anti-arthritic and anti-inflammatory effects. The research findings reveal that guggulipid demonstrates notable anti-arthritic and anti-inflammatory effects by targeting these key molecular pathways. Rigorous human RCT evidence specifically for rheumatoid arthritis remains limited.

Overall assessment: Evidence for anti-inflammatory effects in osteoarthritis from small human studies is preliminary but encouraging. Most mechanistic data comes from in vitro and animal models. Large, well-controlled RCTs in human arthritis populations are lacking.

5.3 Acne (Nodulocystic)

A small but notable clinical trial compared guggul head-to-head with tetracycline, a standard antibiotic, in 20 patients with severe nodulocystic acne. Over three months, guggul reduced inflammatory lesions by 68%, while tetracycline achieved a 65.2% reduction. The difference was not statistically significant, meaning the two treatments performed essentially equally.

A study with 21 participants demonstrated that taking 25 mg of guggulsterone twice daily was as effective as tetracycline in treating acne. Additionally, people with oily skin responded significantly better to guggulsterone than to tetracycline treatment.

Overall assessment: Other potential uses of guggul have no more than minimal supporting evidence. One small study hints that guggul might be helpful for acne. The acne trials are among the more intriguing human findings for guggul, but sample sizes are very small and study designs limit generalizability.

5.4 Obesity and Weight Management

Guggul has been promoted as a weight-loss agent, supposedly working by enhancing thyroid function. However, the evidence that guggul affects the thyroid comes from a study in mice, and one small, double-blind, placebo-controlled trial failed to find it effective for weight loss. This area is considered preliminary, with the existing animal data not yet translated to meaningful human clinical evidence.

5.5 Inflammatory Bowel Disease (IBD)

Guggulsterone can be used for the treatment of inflammatory bowel disease (IBD), a disease characterized by chronic inflammation and damage in the gastrointestinal tract. In various preclinical studies, it has inhibited NF-κB, an important pathway in the pathophysiology of IBD. Available reviews summarize preclinical studies on this topic for providing more insights into the mechanism. Human clinical trial data in IBD specifically remain absent; findings to date are preclinical only.

5.6 Cancer (Preclinical Only)

Numerous studies have shown that guggulsterone induces apoptosis in different cancers such as liver cancer, colon cancer, and cholangiocarcinoma. Guggulsterone has been found to inhibit tumor cell proliferation, induce S-phase arrest, and promote apoptosis through activation of c-Jun N-terminal kinase, suppression of the Akt pathway, and downregulation of anti-apoptotic gene products. These findings are entirely from in vitro and animal models. No clinical trials in humans for cancer treatment or prevention have been conducted or are published.

5.7 Thyroid Function

Guggul might increase thyroid hormone in the body. This effect has been demonstrated in animal models, but the evidence that guggul affects the thyroid comes from animal models, and no large human trials have confirmed the same thyroid-boosting effect. The clinical significance in humans remains unestablished.

---

6. Body Systems and Health Areas Associated with Guggul

• Cardiovascular system: Lipid-lowering (cholesterol, triglycerides, LDL), antiplatelet, anti-atherogenic effects documented preclinically and in some human trials.
• Musculoskeletal system: Anti-arthritic, anti-inflammatory applications in osteoarthritis and rheumatoid arthritis.
• Integumentary system (skin): Nodulocystic acne, skin disorders; traditional use in wound healing.
• Endocrine system: Potential thyroid-stimulating activity; lipid and metabolic regulatory roles.
• Gastrointestinal system: Traditional uses for constipation, hemorrhoids; preclinical evidence for IBD.
• Oncology (preclinical): In vitro and animal evidence for anti-proliferative and pro-apoptotic activity.
• Metabolic/weight management: Traditional use in obesity; weak and inconclusive human evidence.

Considerable scientific evidence indicates the use of gum guggul as a therapeutic agent in the treatment of inflammation, nervous disorders, hyperlipidaemia and associated cardiac disorders such as hypertension and ischaemia, skin disorders, cancer, and urinary disorders.

---

7. Dosage Forms and Dosages Reported in Studies

The minimum effective dose of guggul extract typically ranges from 500 mg to 2 grams per day. Most studies utilize doses between 1 to 3 grams per day. The maximum safe dose is not well-established, and caution is advised beyond 3 grams per day.

Specific dosages reported in clinical studies include:

• In a US clinical trial of hyperlipidaemia, 75 to 150 mg of standardized guggulsterones were administered daily.
• In a study evaluating the anti-inflammatory effect of guggul, 500 mg of gum guggul was taken 3 times per day.
• For severe (nodulocystic) acne, a twice daily dose of guggul that contains up to 25 mg of the active ingredients called guggulsterones was used in research.
• Guggul has most often been used by adults in doses of 0.5–1 gram by mouth three times daily for up to 75 weeks.
• In a European placebo-controlled trial, subjects were administered either Guggulu and Triphala or placebo three times daily for 3 months, with 3 months of follow-up after the end of treatment.

There are no specific timing recommendations, but guggul is generally taken with meals to reduce gastrointestinal side effects. Limited data is available on the absorption and bioavailability of guggul, indicating a need for further research to fully elucidate its pharmacokinetic properties and mechanisms of action.

---

8. Safety Considerations and Drug Interactions

General Tolerability

Guggul is generally well tolerated when taken orally. The most common side effects reported include belching, bloating, diarrhea, headache, nausea, vomiting, and allergic/non-allergic skin reactions. Topical use of guggul may cause allergic contact dermatitis in sensitive individuals. Adverse reactions are more common with higher doses, such as 6,000 mg per day.

Hypersensitivity

In a placebo-controlled RCT, two participants in the intervention group developed hypersensitivity rash (4.3%) compared with none in the placebo group. This suggests a real, if uncommon, risk of allergic skin reactions in some individuals.

Duration of Use

Safety of use beyond 4 months has not been well studied.

Pregnancy and Lactation

Guggul is likely unsafe during pregnancy. It seems to encourage menstrual flow and stimulate the uterus, so some researchers have raised concerns that it might endanger the pregnancy. Not enough is known about the safety of using guggul during breastfeeding. Use should be avoided if pregnant or breastfeeding.

Bleeding Risk

Guggul can slow blood clotting and might cause bleeding or bruising in people with bleeding disorders. Guggul might increase the risk of bleeding during and after surgery. It should be stopped at least 2 weeks before a scheduled surgery.

Hormonal and Thyroid Conditions

Guggul might act like estrogen in the body. If a person has any condition that might be made worse by exposure to estrogen, guggul should not be used. Guggul might interfere with treatment for both hypothyroidism and hyperthyroidism.

Drug Interactions

Guggul may interact with certain drugs and supplements, including anticoagulant/antiplatelet drugs, contraceptive drugs, cytochrome P450 3A4 (CYP3A4) substrates, diltiazem, estrogens, propranolol, rosuvastatin, tamoxifen, and thyroid hormone.

• Diltiazem: Taking guggul can decrease how much diltiazem the body absorbs, and may decrease the effects of diltiazem.
• Propranolol: Guggul decreases levels of propranolol by inhibition of GI absorption. This applies only to the oral form of both agents.
• Rosuvastatin: Guggul might increase how much rosuvastatin the body absorbs. Taking guggul along with rosuvastatin might increase the effects and side effects of rosuvastatin.
• Estrogens and oral contraceptives: Large amounts of guggul might theoretically increase the side effects of estrogen. Estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.
• Thyroid hormones: Guggul might increase thyroid hormone in the body. Taking guggul along with thyroid hormone pills might increase the effects and side effects of thyroid hormones.
• Anticoagulants/antiplatelets: Due to its blood-thinning properties, guggul may potentiate the effects of anticoagulant and antiplatelet medications.

Conservation and Quality Concerns

There has been a decline in the wild population of C. wightii over the last several decades, as a result of habitat loss and degradation coupled with unregulated harvesting and tapping of oleo-gum resin. The species is consequently assessed as Critically Endangered and enlisted in the IUCN Red List of threatened species. This raises the possibility of adulteration or substitution in commercial products, a concern relevant to quality assurance.

---

9. Summary of Evidence Strength

• Lipid-lowering (cholesterol): Mixed human evidence; some earlier small Indian trials positive, but a high-quality 2003 JAMA RCT and a 2020 European RCT both failed to confirm clinically meaningful lipid reduction vs. placebo. Overall: insufficient/conflicting evidence.
• Anti-inflammatory / Arthritis: Strong preclinical mechanistic data; limited small human trials with positive signals for osteoarthritis. Overall: preliminary/promising but insufficient.
• Nodulocystic Acne: Two small head-to-head trials vs. tetracycline showing comparable efficacy. Overall: preliminary; requires larger RCTs.
• Obesity / Weight Loss: Animal data only for thyroid-stimulating mechanism; one small human trial negative. Overall: insufficient human evidence.
• IBD: Preclinical only. Overall: insufficient human evidence.
• Cancer: In vitro and animal models only. Overall: no human clinical evidence.

References

• Sarup P, et al. Pharmacology and Phytochemistry of Oleo-Gum Resin of Commiphora wightii (Guggulu). Scientifica, 2015. PMC4637499.
• Sarup P, et al. Pharmacology and Phytochemistry of Oleo-Gum Resin of Commiphora wightii (Guggulu). Wiley Online Library / Scientifica, 2015.
• Phytochemistry of Guggul (Commiphora wightii): A Review. ResearchGate, 2013.
• Bioactive constituents from gum guggul (Commiphora wightii). Phytochemistry, ScienceDirect, 2001.
• Owsley E, Chiang JY. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochemical and Biophysical Research Communications, 2003. PubMed 12705905.
• The Hypolipidemic Agent Guggulsterone Regulates the Expression of Human Bile Salt Export Pump. PMC4114705.
• Cui J, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem, 2003. PubMed 12525500.
• Ulbricht C, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complementary Therapies in Medicine, 2005. PubMed 16338199.
• DARE: Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. NCBI Bookshelf.
• Szapary PO, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA, 2003;290(6):765-72. PubMed 12915429.
• Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial. PubMed 33242870.
• Exploring the Promising Role of Guggulipid in Rheumatoid Arthritis Management. PubMed 38284718.
• Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases. Frontiers in Pharmacology / PMC6087759.
• Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases. Frontiers in Pharmacology, 2018.
• The role of guggulsterone on the NF-κB pathway in inflammatory bowel disease: preclinical evidence. PMC9327637.
• Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. PubMed 16250653.
• Guggulsterone, a farnesoid X receptor antagonist, lowers plasma trimethylamine-N-oxide levels. PubMed 30526076.
• Guggul Uses, Benefits & Dosage. Drugs.com Natural Product Database.
• Guggul: Health Benefits, Side Effects, Uses, Dose & Precautions. RxList.
• Guggul (Commiphora mukul) drug interactions and dosing. Medscape Reference.
• Commiphora wightii — Overview. ScienceDirect Topics.
• Guggul's Therapeutic Uses. EBSCO Research Starters: Complementary and Alternative Medicine.